Dyadic International (NASDAQ:DYAI) Share Price Breaks Below 50-Day Moving Average – Should You Sell?

Posted by Stanley Muller on Oct 1st, 2026

Dyadic International Inc. (NASDAQ:DYAI – Get Free Report)’s stock price crossed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $0.72 and traded as low as $0.4351. Dyadic International shares last traded at $0.4660, with a volume of 116,708 shares trading hands.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Dyadic International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $3.00.

View Our Latest Stock Report on DYAI

Dyadic International Stock Down 3.4%

The company’s fifty day moving average price is $0.70 and its 200-day moving average price is $0.80. The stock has a market cap of $17.21 million, a P/E ratio of -1.87 and a beta of 0.96. The company has a debt-to-equity ratio of 4.08, a quick ratio of 1.65 and a current ratio of 1.65.

Dyadic International (NASDAQ:DYAI – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Dyadic International had a negative return on equity of 2,920.31% and a negative net margin of 201.43%.The firm had revenue of $0.96 million for the quarter, compared to analysts’ expectations of $1.02 million. Equities analysts forecast that Dyadic International Inc. will post -0.15 EPS for the current year.

Hedge Funds Weigh In On Dyadic International

A hedge fund recently bought a new stake in Dyadic International stock. BlackRock Inc. bought a new position in Dyadic International Inc. (NASDAQ:DYAI – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 197,749 shares of the biotechnology company’s stock, valued at approximately $177,000. BlackRock Inc. owned 0.54% of Dyadic International as of its most recent SEC filing. 27.95% of the stock is owned by institutional investors and hedge funds.

Dyadic International Company Profile

(Get Free Report)

Dyadic International, Inc is a biotechnology company that develops microbial-based technologies for producing proteins and other biological materials. Its platforms are designed to enable the cost-effective development and manufacture of vaccines, therapeutic proteins, enzymes, and other biologic products.

The company’s technology portfolio includes the C1 protein-production platform, which uses a proprietary fungal microorganism to produce recombinant proteins, and additional microbial expression systems intended to support applications in biopharmaceuticals, animal health, food and nutrition, and industrial biotechnology.